drug-development

AI is transforming U.S. pharmaceutical R&D by accelerating drug discovery, preclinical testing, clinical trials, and regulatory review, with early evidence suggesting it could cut development times by roughly half and reduce costs.

UCLA researchers developed DDL-920, a drug mimicking stroke rehabilitation effects in mice, published in Nature Communications. This breakthrough targets parvalbumin neurons to restore gamma oscillations and improve movement control.